drugset / Trial / NCT06317311

A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer

NCT06317311

Phase 2 Active not recruiting 41 enrolled GlaxoSmithKline
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical trial is to understand the effectiveness of dostarlimab and carboplatin-paclitaxel followed by dostarlimab monotherapy in participants with endometrial cancer

Timeline

Start
2024-05-07
Primary completion
2026-07-15
Completion
2027-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule 5 unknown Intravenous
Subject Dostarlimab Monoclonal antibody 1000 mg Intravenous
Subject Paclitaxel Small molecule 175 mg/m2 Intravenous

Indications